Juvenile xanthogranuloma - Xanthogranuloma Jivenilhttps://en.wikipedia.org/wiki/Juvenile_xanthogranuloma
☆ Nan rezilta Stiftung Warentest 2022 ki soti nan Almay, satisfaksyon konsomatè yo ak ModelDerm te sèlman yon ti kras pi ba pase ak konsiltasyon telemedsin peye. Li se karakteristik yo gen yon aparans yon ti kras jòn.
Nodil jòn nan timoun yo. Tipik Xanthogranuloma Jivenil (Juvenile xanthogranuloma)
relevance score : -100.0%
References Juvenile Xanthogranuloma 30252359 NIH
Juvenile xanthogranuloma (JXG) se yon kondisyon ki ase komen ak kalite non-Langerhans cell histiocytic disorder ki pi souvan nan timoun yo. Nan apeprè 75% nan ka, blesi sa yo parèt nan premye ane a nan lavi, ak plis pase 15-20% nan pasyan yo gen yo depi yo fèt. Pandan ke ra nan adilt, JXG tipikman rive pi souvan nan moun nan fen ven yo nan trant, ak pifò pasyan adilt yo gen yon sèl blesi. Klinikman, li parèt tankou yon sèl oswa plizyè jòn-zoranj-mawon boul oswa boul fèm, sitou sou figi a, kou, ak anwo kò a. Blesi nan bouch yo pa komen, men yo ka parèt tankou yon boul jòn sou kote sa yo nan lang lan oswa yon lòt kote nan bouch la, petèt ki mennen nan maladi ilsè ak senyen. Blesi po anjeneral pa lakòz sentòm epi yo gen tandans ale pou kont yo pandan plizyè ane. Malgre ke ra, patisipasyon okulèr se pwoblèm ki pi komen pi lwen pase po a, ki te swiv pa patisipasyon nan poumon. Ocular JXG tipikman afekte sèlman yon sèl je epi li rive nan mwens pase 0. 5 % nan pasyan yo, menm si apeprè 40% nan moun ki gen patisipasyon okulèr tou gen plizyè blesi po lè yo dyagnostike.
Juvenile xanthogranuloma (JXG) is a relatively common entity and is the most common form of non-Langerhans cell histiocytic disorder of childhood., It is estimated that in 75% of cases, lesions appear during the first year of life, with >15-20% of patients having lesions at birth. JXG is rare in adults, with a peak incidence in the late twenties to thirties. The majority of adult patients have solitary lesions. Typically, the clinical presentation consists of solitary or multiple yellow-orange-brown firm papules or nodules. The most common locations are the face, neck, and upper torso. Oral lesions are rare and often occur as a yellow nodule on the lateral aspects of the tongue. Oral lesions can also arise on the gingival, buccal mucosa, and midline hard palate and may ulcerate and bleed. Cutaneous lesions are usually asymptomatic, and most lesions spontaneously involute over the course of several years. Although occurring rarely, ocular involvement is the most common extracutaneous site involved, followed by the lungs. Ocular JXG is nearly always unilateral and develops in less than 0.5% of patients. Approximately 40% of patients with ocular JXG, however, have multiple cutaneous lesions at the time of diagnosis.
Juvenile Xanthogranuloma: An Entity With a Wide Clinical Spectrum 32721389Juvenile xanthogranulomas (JXGs) yo pa komen, maladi benign ki fè pati yon pi gwo kategori nan non-Langerhans cell histiocytoses. Yo anjeneral parèt kòm youn oswa plis boul wouj oswa jòn, souvan yo jwenn sou tèt la oswa kou. Pifò JXG yo devlope swa nan nesans oswa nan premye ane lavi yo. Pandan ke li pa nòmal, pafwa yo ka afekte zòn pi lwen pase po a, ak patisipasyon je yo se yon bagay yo gade pou dapre literati ki egziste deja. Anjeneral, JXG sou po a ale poukont yo epi anjeneral pa bezwen tretman.
Juvenile xanthogranulomas (JXGs) are uncommon, benign diseases that are part of a larger category of non-Langerhans cell histiocytoses. They typically show up as one or more red or yellowish lumps, often found on the head or neck. Most JXGs develop either at birth or within the first year of life. While it's unusual, sometimes they can affect areas beyond the skin, with eye involvement being something to watch for according to existing literature. Generally, JXGs on the skin go away on their own and typically don't need treatment.
Lezyon okilè manifeste nan jiska 10% nan moun ki gen JXG epi li ka afekte vizyon yo. Malgre ke blesi kutane anjeneral disparèt espontaneman, blesi okulèr raman amelyore espontaneman epi yo mande tretman.